Parkinson's disease historical perspective

Revision as of 15:28, 21 December 2018 by Fahimeh Shojaei (talk | contribs)
Jump to navigation Jump to search

Parkinson's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parkinson's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Neurocognitive Disorder Due to Parkinson's Disease

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parkinson's disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parkinson's disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parkinson's disease historical perspective

CDC on Parkinson's disease historical perspective

Parkinson's disease historical perspective in the news

Blogs on Parkinson's disease historical perspective

Directions to Hospitals Treating Parkinson's disease

Risk calculators and risk factors for Parkinson's disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

the first person who documented and recognized Parkinson’s disease was a British physician, James Parkinson in 1817 who named it paralysis agitans. The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients. in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.

Historical Perspective

Discovery

  • Parkinson disease’s symptoms have been known for many years but the first person who documented and recognized Parkinson’s disease was a British physician, James Parkinson in 1817 who named it paralysis agitans.
  • The current name of the disease (Parkinson disease) is from Jean-Martin Charcot.
  • The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients.
  • Later on in 1919 Tretiakoff showed that in this patients’ substantia nigra there are evidences of neuronal loss.
  • Finally in the 1950s dopamine depletion was known to be the underlying cause of the disease.[1]
  • Later, in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.[2][3][4]

Landmark Events in the Development of Treatment Strategies

Famous Cases

References

  1. Hornykiewicz O (2006). "The discovery of dopamine deficiency in the parkinsonian brain". J. Neural Transm. Suppl. (70): 9–15. PMID 17017502.
  2. Manyam BV, Sánchez-Ramos JR (1999). "Traditional and complementary therapies in Parkinson's disease". Adv Neurol. 80: 565–74. PMID 10410773.
  3. Parkinson J (2002). "An essay on the shaking palsy. 1817". J Neuropsychiatry Clin Neurosci. 14 (2): 223–36, discussion 222. doi:10.1176/jnp.14.2.223. PMID 11983801.
  4. Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520.<ref name="pmid5637779">Cotzias GC (March 1968). "L-Dopa for Parkinsonism". N. Engl. J. Med. 278 (11): 630. PMID 5637779.

Template:WH Template:WS